海南海藥(000566.SZ)孫公司擬斥不超1000萬美元參投海外基金
格隆匯11月4日丨海南海藥(000566.SZ)公佈,公司全資孫公司海藥國際集團有限公司(“海藥國際”)擬參與投資Apricot BioScience Holdings, L.P.(“海外基金”)。海外基金的普通合夥人Apricot Biotech Holdings Limited認繳海外基金50萬美元出資額,海外基金設立規模為1億美元。海藥國際擬出資不超過1000萬美元成為海外基金的有限合夥人,其他有限合夥人認繳剩餘部分。公司董事會授權公司管理層在投資金額不超過1000萬美元的額度內,簽署相關投資協議。
合夥協議顯示,海外基金投資領域為生物醫藥及醫療服務業。
通過投資海外基金,能夠充分利用專業的基金管理團隊的投資經驗和風險控制體系,利用海外基金有效地對海外前沿、優質項目進行戰略投資,挖掘有價值的海外醫藥醫療項目,提升公司的核心競爭力和盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.